Hantz Financial Services Inc. Raises Stock Holdings in Enovis Co. (NYSE:ENOV)

Hantz Financial Services Inc. grew its stake in shares of Enovis Co. (NYSE:ENOV) by 10.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 247,469 shares of the company’s stock after buying an additional 23,073 shares during the period. Hantz Financial Services Inc. owned 0.44% of Enovis worth $10,859,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ENOV. Diamond Hill Capital Management Inc. grew its stake in Enovis by 7.8% during the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company’s stock valued at $129,352,000 after acquiring an additional 218,660 shares in the last quarter. Royce & Associates LP increased its holdings in shares of Enovis by 16.8% in the third quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock worth $103,479,000 after purchasing an additional 346,317 shares during the last quarter. State Street Corp lifted its position in shares of Enovis by 4.3% in the third quarter. State Street Corp now owns 1,647,220 shares of the company’s stock worth $70,913,000 after buying an additional 68,190 shares in the last quarter. River Road Asset Management LLC bought a new position in Enovis during the third quarter valued at approximately $51,341,000. Finally, Geode Capital Management LLC grew its holdings in Enovis by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company’s stock valued at $39,678,000 after buying an additional 80,165 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ENOV. Evercore ISI decreased their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and set a $65.00 price objective on shares of Enovis in a research report on Thursday, November 7th. Finally, JMP Securities assumed coverage on Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $65.86.

Enovis Stock Up 0.4 %

Enovis stock opened at $47.89 on Wednesday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a market cap of $2.68 billion, a P/E ratio of -21.87 and a beta of 1.94. The business has a fifty day moving average of $46.02 and a two-hundred day moving average of $44.49. Enovis Co. has a twelve month low of $38.27 and a twelve month high of $65.03.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. The business had revenue of $505.22 million for the quarter, compared to analysts’ expectations of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company’s revenue was up 21.0% compared to the same quarter last year. During the same period last year, the business earned $0.56 EPS. On average, analysts forecast that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.